1. Home
  2. IDN vs MGNX Comparison

IDN vs MGNX Comparison

Compare IDN & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellicheck Inc.

IDN

Intellicheck Inc.

HOLD

Current Price

$5.51

Market Cap

103.0M

Sector

Technology

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$2.85

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDN
MGNX
Founded
1994
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.0M
115.8M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
IDN
MGNX
Price
$5.51
$2.85
Analyst Decision
Strong Buy
Hold
Analyst Count
3
5
Target Price
$7.33
$3.40
AVG Volume (30 Days)
96.2K
1.4M
Earning Date
03-19-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
220.00
N/A
EPS
0.06
N/A
Revenue
$4,433,454.00
$149,500,000.00
Revenue This Year
$12.21
N/A
Revenue Next Year
$12.44
$16.14
P/E Ratio
N/A
N/A
Revenue Growth
23.21
N/A
52 Week Low
$2.30
$0.99
52 Week High
$7.48
$3.50

Technical Indicators

Market Signals
Indicator
IDN
MGNX
Relative Strength Index (RSI) 61.49 61.95
Support Level $5.12 $1.46
Resistance Level $5.74 $3.50
Average True Range (ATR) 0.27 0.23
MACD 0.08 0.02
Stochastic Oscillator 51.59 59.47

Price Performance

Historical Comparison
IDN
MGNX

About IDN Intellicheck Inc.

Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: